Plus: a Cornwall cottage, an upstate New York cafe serving up dumplings and more recommendations from T Magazine.
16h
GlobalData on MSNAardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drugAardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Researchers compared how three antioxidants affected gray hair outcomes in mice: hesperetin, diosmetin, and luteolin, and ...
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results